Key facts
- This page summarizes Jodi Devlin's Form 4 filing for TriSalus Life Sciences, Inc. (TLSI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Jan 2025, 18:00.
Jodi Devlin - 27 Jan 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)
- Reporting relationship
- Chief of COMMERC. OPERATIONS
- Issuer ticker
- TLSI
- Reported as of
- 27 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jan 2025, 18:00:33 UTC
- Prior SEC filing
- 14 Feb 2024
- Next SEC filing
- 19 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Murphy, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jodi Devlin filed Form 4 for TriSalus Life Sciences, Inc. (TLSI) on 29 Jan 2025.
Change
- Previous filing in this sequence was filed on 14 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TLSI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,625
- Change %
- +61%
- Price
- $0.000000
- Shares after
- 28,125
- Date
- 27 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLSI
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +63,750
- Change %
- Price
- $0.000000
- Shares after
- 63,750
- Date
- 27 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 63,750
- Exercise price
- $5.30
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
Footnote F2
One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.